The shares of AbbVie Inc. (NYSE:ABBV) and AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) were among the active stocks of the last trading sessions. AbbVie Inc. (NYSE:ABBV) soared to 0.46% closing at the price of $94.81 whereas the shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) soared 2.75% with the increase of 0.08 points closing at the price of $2.99. AbbVie Inc. has currently increase 1.27% in its stock over the period of 6-months while its rival AcelRx Pharmaceuticals, Inc. added 32.89% in the previous 6-months.
Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.
Returns and Profitability
Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.
The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of AbbVie Inc. (NYSE:ABBV) is 17.8% while the ROI of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is -5.9%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, ABBV’s EBITDA Margin is 13.66 whereas ACRX’s is -4.58.
Both the profitability ratios suggest that AbbVie Inc. (NYSE:ABBV) is more suitable investment in terms of profitability and return.
EPS & Surprise Factor
AbbVie Inc. (NYSE:ABBV) reported $2/share EPS for the previous quarter where analysts were predicting an EPS to be $1.97/share Thus beating the analyst Estimates with a Surprise Factor of 1.5 Percent. While, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) reported EPS of $-0.2/share in the last quarter. The analysts projected EPS of $-0.2/share depicting a Surprise of 0 Percent.
Taking a look at Earnings per Share, AbbVie Inc. tends to be beating the analyst estimates more than AcelRx Pharmaceuticals, Inc.. so ABBV is more profitable than ACRX.
Technical Analysis of AbbVie Inc. & AcelRx Pharmaceuticals, Inc.
Moving average convergence divergence (MACD) shows that AbbVie Inc. (NYSE:ABBV) is on a PRICE RELATIVITY trend While AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the AbbVie Inc. was in BULLISH territory and AcelRx Pharmaceuticals, Inc. was in BEARISH territory.
ABBV’s current statistics gauge that the stock candle is BULLISH with LOW volatility. While ACRX’s candle is BEARISH with HIGH.
EPS Growth Rate: ABBV’s 15.36% versus ACRX’s 0%
Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of AbbVie Inc. (NYSE:ABBV) is predicted at 15.36% while AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) stands at 0%. These numbers suggest that ABBV is more suitable investment in terms of EPS growth rate.
Financial Risk and Liquidity Concerns
The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of ABBV stands at 0.8 while ACRX is at 4 whereas the debt ratio of the prior is 0 while the debt ratio of the later is 0.
The values of the both ratios suggest that one is more liquid and other investment is more risk free.
While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 2.5 for ABBV and 2.3 for ACRX which means ABBV has Hold rating whereas ACRX has Hold rating.
Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for ABBV is $109.83 which is 13.68% of its current price while ACRX has price target of 5.6 which is 46.61% of its current price.
Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.
ABBV currently has price to earning P/E ratio of 22.13 whereas ACRX has 0 while the forward P/E ratio for the prior stands at 10.66 and for the later it depicts the value of 0.
The price to Book P/B for ABBV is 0, Price to Sale is at 4.8 and for ACRX these ratios stand at 0 and 56.6.